Tetanus is an acute traumatic infectious disease caused by the invasion of Clostridium tetani (tetanus bacillus). Currently, prevention is mainly through: tetanus vaccination to enable the body to produce acquired immunity; injection of tetanus antitoxin or tetanus human immunoglobulin to enable the body to immediately acquire immunity for the treatment of tetanus and short-term emergency prevention. Among them, monoclonal antibodies are widely used in the development of specific target drugs due to their unique advantages, and have great potential in tumor treatment and the prevention and treatment of infectious diseases. With the development and iteration of monoclonal antibody drug development technology, it has developed from mouse antibodies to fully human monoclonal antibodies.

The company's fully human anti-tetanus toxin monoclonal antibody A82/B86 injection combination preparation is a Class I new drug for therapeutic biological products. Compared with heterologous serum, mouse antibodies, humanized antibodies and chimeric antibodies, fully human antibodies can minimize the host's heterogeneity to ensure product safety, and at the same time have excellent production capacity to meet market demand. During the reporting period, the fully human anti-tetanus toxin monoclonal antibody A82/B86 injection combination preparation started Phase I/II clinical trials for the prevention of tetanus, and is currently undergoing Phase I clinical trials.